Hawthorn and heart failure
What 3 graded rows on hawthorn agree on for heart failure, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Hawthorn page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Hawthorn page, with its PubMed record.
Your question
Hawthorn and heart failure
3 rows · 3,656 peopleMostly no difference: 2 of 3 rows, and most of the people. 1 found an improvement.
- CGrade C× 1
- ∅No effect× 2
- Rows
- 3
- Trials
- 12
- People
- 3,656
- Pooled reviews may count some twice
Where they differ
From the rowsThe best-graded row, grade C, is a systematic review of 855 people (2008) and found an improvement. 2 rows are graded No effect, our grade for adequately powered trials that found no effect.
The row that found an improvement is a pooled review of several trials; the 2 rows that found no difference are single studies.
The rows
1 improved · 2 no difference- ∅No effectTime to first cardiac event in heart failure · No difference
RCT · n 2,681 · 2008 · Adults with NYHA class II–III heart failure and ejection fraction ≤35% on standard therapy
900 mg/day · 24 months
Cardiac events occurred in 27.9% versus 28.9% on placebo (hazard ratio 0.95, not significant); cardiac death trended lower but not significantly; adverse events were similar.
- ∅No effectWalking distance and quality of life in heart failure · No difference
RCT · n 120 · 2009 · Ambulatory adults with NYHA class II–III heart failure on standard therapy
450 mg twice daily · 6 months
No difference in 6-minute walk, quality of life or functional capacity; ejection fraction differed slightly in favour of hawthorn, and adverse events were more frequent on hawthorn.
- CGrade CExercise capacity and symptoms in chronic heart failure · Improved
Systematic review, 10 studies · n 855 · 2008 · Patients with NYHA class I–III heart failure, mostly on conventional treatment
Varied across trials · Varied across trials
Maximal workload rose 5.35 W and breathlessness and fatigue scores improved versus placebo; mortality and cardiac events were not reported.